Role of nucleic acid-based polymeric micelles in treating lung diseases

Kaur, J; Gulati, M; Corrie, L; Awasthi, A; Jha, NK; Chellappan, DK; Gupta, G; MacLoughlin, R; Oliver, BG; Dua, K; Singh, SK

Role of nucleic acid-based polymeric micelles in treating lung diseases

Kaur, J Gulati, M Corrie, L Awasthi, A Jha, NK Chellappan, DK Gupta, G MacLoughlin, R Oliver, BG Dua, K

Singh, SK

Permalink

Publisher:: Future Medicine Ltd
Publication Type:: Journal Article
Citation:: Nanomedicine

Closed Access

	Filename	Description	Size
	Nucleic acid_Micelles_Lung Diseases_nnm-2022-0260.pdf	Published version	4.65 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Kaur, J
dc.contributor.author	Gulati, M
dc.contributor.author	Corrie, L
dc.contributor.author	Awasthi, A
dc.contributor.author	Jha, NK
dc.contributor.author	Chellappan, DK
dc.contributor.author	Gupta, G
dc.contributor.author	MacLoughlin, R
dc.contributor.author	Oliver, BG
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	Singh, SK
dc.date.accessioned	2023-01-06T11:09:45Z
dc.date.available	2023-01-06T11:09:45Z
dc.identifier.citation	Nanomedicine
dc.identifier.issn	1743-5889
dc.identifier.issn	1748-6963
dc.identifier.uri	http://hdl.handle.net/10453/164756
dc.description.abstract	<jats:p> The prevalence of lung diseases is increasing year by year and existing drug therapies only provide symptomatic relief rather than targeting the actual cause. Nucleic acids can be used as an alternative therapeutic approach owing to their potential to reform a homeostatic balance by upregulating protective genes or downregulating damaging genes. However, their inherent properties, such as poor stability, ineffective cellular uptake, negative charge and so on, hinder their clinical utility. Such limitations can be overcome by exploiting the functional chemistry of polymeric micelles (PMs) for site-specific delivery, transfection efficiency and improved stability. With this objective, the present work describes the advancements made in designing nucleic acid-based PMs for treating lung diseases followed by approaches requiring consideration for clinical applications. </jats:p>
dc.language	en
dc.publisher	Future Medicine Ltd
dc.relation.ispartof	Nanomedicine
dc.relation.isbasedon	10.2217/nnm-2022-0260
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	0306 Physical Chemistry (incl. Structural), 1004 Medical Biotechnology, 1007 Nanotechnology
dc.subject.classification	Nanoscience & Nanotechnology
dc.title	Role of nucleic acid-based polymeric micelles in treating lung diseases
dc.type	Journal Article
utslib.for	0306 Physical Chemistry (incl. Structural)
utslib.for	1004 Medical Biotechnology
utslib.for	1007 Nanotechnology
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
utslib.copyright.status	closed_access	*
dc.date.updated	2023-01-06T11:09:40Z
pubs.publication-status	Published online

Abstract:

The prevalence of lung diseases is increasing year by year and existing drug therapies only provide symptomatic relief rather than targeting the actual cause. Nucleic acids can be used as an alternative therapeutic approach owing to their potential to reform a homeostatic balance by upregulating protective genes or downregulating damaging genes. However, their inherent properties, such as poor stability, ineffective cellular uptake, negative charge and so on, hinder their clinical utility. Such limitations can be overcome by exploiting the functional chemistry of polymeric micelles (PMs) for site-specific delivery, transfection efficiency and improved stability. With this objective, the present work describes the advancements made in designing nucleic acid-based PMs for treating lung diseases followed by approaches requiring consideration for clinical applications.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/164756